文献速递神经肿瘤

原发性脑肿瘤的分子匹配靶向治疗:单中心回顾性分析

Molecular matched targeted therapies for primary brain tumors-a single center retrospective analysis.
PubMed 文献 · J Neurooncol · 2022-07-21

在德国法兰克福大学医院2008至2021年回顾性分析中,共识别413次超说明书治疗,其中37次(9%)为基于分子标志物的靶向治疗,最常见于胶质瘤和脑膜瘤;首次随访MRI部分缓解13.5%、疾病稳定29.7%、疾病进展46.0%,无新的安全性信号,无CTCAE 5级不良事件。

要点

  • 413次超说明书治疗中37次(9%)为分子匹配靶向治疗,2016年后年治疗数增加。
  • 首次随访MRI:部分缓解13.5%、疾病稳定29.7%、疾病进展46.0%,无CTCAE 5级不良事件。
  • 至少疾病稳定者中位无进展生存期9.1个月、总生存期18个月;进展者分别为1.8个月和3.6个月。

核心结论

  • 可靶向的分子变异范围广泛,但疗效主要在具有范例性致癌驱动因素的肿瘤中观察到,尤其是BRAF突变。
  • 作者认为迫切需要对基于生物标志物的分子匹配治疗开展进一步研究。

研究设计与样本

  • 单中心回顾性分析,纳入2008年至2021年在法兰克福大学医院(歌德大学)接受超说明书靶向治疗的原发性脑肿瘤患者。
  • 分析用于指导分子超说明书治疗的分子变异类型及其评估的诊断流程,并收集耐受性和结局数据。

主要发现

  • 共识别413次超说明书治疗,2016年后年治疗数增加;其中37次(9%)为基于分子标志物的靶向治疗。
  • 接受分子匹配靶向治疗最常见的肿瘤类型为胶质瘤和脑膜瘤,罕见类型包括髓母细胞瘤和乳头状颅咽管瘤。
  • 分子靶向方法包括检查点抑制剂以及mTOR、FGFR、ALK、MET、ROS1、PIK3CA、CDK4/6、BRAF/MEK和PARP抑制剂。
  • 首次随访MRI显示部分缓解13.5%、疾病稳定29.7%、疾病进展46.0%。
  • 至少疾病稳定患者的中位无进展生存期为9.1个月、中位总生存期为18个月;首次随访MRI进展患者分别为1.8个月和3.6个月。

关键数值与推荐

  • 分子匹配靶向治疗37次(9%),基于分子标志物选择。
  • 首次随访MRI疗效:部分缓解13.5%、疾病稳定29.7%、疾病进展46.0%。
  • 至少疾病稳定者中位无进展生存期9.1个月、中位总生存期18个月;进展者中位无进展生存期1.8个月、中位总生存期3.6个月。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Molecular diagnostics including next generation gene sequencing are increasingly used to determine options for individualized therapies in brain tumor patients. We aimed to evaluate the decision-making process of molecular targeted therapies and analyze data on tolerability as well as signals for efficacy. METHODS: Via retrospective analysis, we identified primary brain tumor patients who were treated off-label with a targeted therapy at the University Hospital Frankfurt, Goethe University. We analyzed which types of molecular alterations were utilized to guide molecular off-label therapies and the diagnostic procedures for their assessment during the period from 2008 to 2021. Data on tolerability and outcomes were collected. RESULTS: 413 off-label therapies were identified with an increasing annual number for the interval after 2016. 37 interventions (9%) were targeted therapies based on molecular markers. Glioma and meningioma were the most frequent entities treated with molecular matched targeted therapies. Rare entities comprised e.g. medulloblastoma and papillary craniopharyngeoma. Molecular targeted approaches included checkpoint inhibitors, inhibitors of mTOR, FGFR, ALK, MET, ROS1, PIK3CA, CDK4/6, BRAF/MEK and PARP. Responses in the first follow-up MRI were partial response (13.5%), stable disease (29.7%) and progressive disease (46.0%). There were no new safety signals. Adverse events with fatal outcome (CTCAE grade 5) were not observed. Only, two patients discontinued treatment due to side effects. Median progression-free and overall survival were 9.1/18 months in patients with at least stable disease, and 1.8/3.6 months in those with progressive disease at the first follow-up MRI. CONCLUSION: A broad range of actionable alterations was targeted with available molecular therapeutics. However, efficacy was largely observed in entities with paradigmatic oncogenic drivers, in particular with BRAF mutations. Further research on biomarker-informed molecular matched therapies is urgently necessary.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Luger AL, König S, Samp PF, et al. Molecular matched targeted therapies for primary brain tumors-a single center retrospective analysis. J Neurooncol. 2022. PMID: 35864412. doi:10.1007/s11060-022-04049-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。